isolated by using standard density gradient centrifugation. An IFN-γ ELISPOT assay was performed as follows. A 96-well plate containing Immobilon-P membrane (MSIPS4510; Millipore, Billerica, MA, USA) was incubated with monoclonal antimonkey IFN-γ (CT610-10; U-Cytech, Utrecht, the Netherlands) at 4°C overnight and blocked with RPMI medium 1640 (no. 11875-093; Gibco, Grand Island, NY, USA) containing 0.05 mmol/L 2-mercaptoethanol, 1 mmol/L sodium pyruvate, 2 mmol/L Lglutamine, 10 mmol/L HEPES, and 10% fetal bovine serum (no. SH30070; HyClone, Logan, UT, USA) at 37°C for 2 h.
PBMCs were plated at a density of 2.5 × 10 5 cells/well. Recombinant MERSCoV spike protein (no. 40069-V08B; Sino Biologic Inc., North Wales, PA, USA) and SARS-CoV spike S1 subunit (no. 40150-V08B1; Sino Biologic Inc.) were added to the wells at a final concentration of 10 g/mL to stimulate PBMCs. Phosphatebuffered saline was used for mock stimulation. At 24-h poststimulation, IFN-γ was detected by using biotinylated anti-monkey IFN-γ (CT610-10; U-Cytech), and color was developed by using nitro-blue tetrazolium and 5-bromo-4-chloro-3'-indolyphosphate (Pierce, Rockford, IL, USA). Spots were counted by using an ELISPOT reader (Bioreader 4000; BIOSYS, Germany), and the results were reported as number of spot-forming cells/million PBMCs.
Microneutralization Test
Serum samples were heat-inactivated (56°C for 30 min) and mixed with equal 
